EUCTR2005-002088-98-ES进行中（未招募）不适用
Full title of the trial : Estudio multicentrico, multinacional aleatorizado doble ciego con grupos paralelos y controlado con placebo de etil-EPA (etil eicosapentanoato) en pacientes con enfermedad de Huntington.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Written informed consent.
- •Aged 35 or older of either genderHas clinical features of Huntington’s Disease (HD) and a confirmatory family history of HD, and/or a CAG repeat expansion greater than or equal to 36.
- •Maximal dystonia score of 2 or less in both trunk and extremities items.Chorea score of at least 2 in at least one extremity item.
- •Maximal bradykinesia score of 2 or less in each of the items: body, pronation/supination and finger tapping
- •Able to travel to the assessment centre and judged by the Investigator as likely to be able to continue to travel for the duration of the trial.
- •Not considered to have major depression as defined in the DSM-IV-TRNot considered at risk of suicide (must not score positive for item A9 on the DSM-IV-TR).
- •Treatment with neuroleptics (including atypical neuroleptics) is excluded, except when taken at a stable dose for 4 weeks or more prior to visit 1.
- •Not taking tetrabenazine, omega–3 supplements, anticoagulant medication, steroids (other than topical preparations), selenium supplements >55mcg/day, magnesium supplements >150mg/day (including NMDA antagonists), lithium, antiepileptic medication and benzodiazepines. However, benzodiazepines are allowed if taken on a regular basis at a low dose for insomnia e.g. valium 5mg, temazepam 10mg, diazepam and lorazepam 1mg taken at night.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Unable to give written informed consent.
- •Requires 24 hour care and usually bedridden
- •Unlikely to comply with trial visit schedule or with trial medication due to irritability, symptoms of depression or other reason(s)
- •Diagnosis of major depressive disorder as defined in the DSM-IV-TRScore positive for item A9 on the DSM-IV-TR
- •Severe intercurrent illness which, in the opinion of the Investigator, may put the patient at risk when participating in the trial or may influence the results of the trial or affect the patients’ ability to take part in the trial.
- •Clinically significant, abnormal, baseline laboratory result(s), which in the opinion of the Investigator affect(s) the patients suitability for the trial e.g. abnormal TSH.
- •Females who, in the opinion of the Investigator, have the potential of childbearing but are not taking adequate contraceptive precautions; or who are pregnant or lactating.
- •Alcohol and / or drug abuse as defined in theDSM IV criteria for substance abuse - applies to alcohol and / or any illicit drug, including cannabis within the last 12 months.
- •Omega 3 supplementation within 4 weeks of visit 1 and throughout the trial period.
- •Treatment with tetrabenazine – current or within 4 weeks of visit 1.Treatment with neuroleptics (including atypical neuroleptics) except when taken at a stable dose for 4 weeks or more prior to visit 1Treatment with benzodiazepines on a regular basis within 8 weeks of visit 1, except when used at a low doses for insomnia e.g. valium 5mg, temazepam 10mg, diazepam and lorazepam 1mg at night.
- •Treatment with steroids (other than topical preparations) – current or within 4 weeks of visit 1.
- •Selenium supplementation > 55mcg/day within 4 weeks of visit 1.
- •Magnesium supplementation >150mg/day, riluzole or NMDA antagonists (memantine and amantadine) within 4 weeks of visit 1.
- •Treatment with lithium medication – current or within 6 months of visit 0.
- •Treatment with antiepileptic medication – current or within 6 months of visit 0.
- •Have participated in another interventional clinical trial or taken Investigational Medication in the last 3 months.
- •Have participated in any clinical trial with ethyl-EPA.Known allergy to any ingredients of the trial medication or placebo.
- •Currently taking anticoagulants.
研究者
相似试验
进行中（未招募）
不适用
Título completo del ensayo: Estudio multicéntrico, aleatorizado, abierto, de 12 semanas de duración, para determinar el efecto del tratamiento con Myfortic® (micofenolato sódico) en términos de calidad de vida en pacientes con síntomas gastrointestinales (GI) en tratamiento con MMF (micofenolato mofetilo) después de un trasplante renal. - MYVIDA2Trasplante renalEUCTR2005-004024-39-ESovartis Farmacéutica, S.A.250
进行中（未招募）
1 期
ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO, EN FASE 3 DE LA EFICACIA Y SEGURIDAD DE SUNITINIB (SU011248) EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO AVANZADO / METASTÁSICO TRATADOS CON ERLOTINIBA MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTASIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIBCáncer de pulmón no microcítico (CPNM) localmente avanzado o metastásico tras el fracaso de al menos una pauta de quimioterapia previa.Locally advanced or metastasic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimenMedDRA version: 9.1Level: LLTClassification code 10059515Term: Non-small cell lung cancer metastaticEUCTR2007-001915-52-ESPfizer, S.A.956
进行中（未招募）
1 期
A 28 week long study using Xolair to treat patients with Chronic Itch/Hives without known cause.EUCTR2010-022785-27-ESGenentech, Inc.322
进行中（未招募）
不适用
ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, PARA EVALUAR LA EFICACIA, SEGURIDAD Y TOLERABILIDAD DE JNJ-42160443 EN PACIENTES CON NEURALGIA POSTHERPÉTICA Y NEURALGIA POSTRAUMÁTICA, SEGUIDO DE UN PERIODO DE EXTENSIÓN DOBLE CIEGO DE SEGURIDAD Y UNA EXTENSIÓN ABIERTA DE SEGURIDAD.EUCTR2008-007478-39-ESJanssen Cilag International, N.V.200
尚未招募
不适用
Prospective, clinical, multicentric study to evaluate the influence of the length of the membranous urethra on stress urinary incontinence after robot-assisted radical prostatectomyC61Malignant neoplasm of prostateDRKS00024607Krankenhaus der Barmherzigen Brüder Wien500